Table 2 Number of rifampicin-associated adverse reactions reported to Uppsala Monitoring Centre (UMC), the Collaboration Centre of the WHO Programme for International Drug Monitoring

Total rifampicin-associated reports

37,812

192

Drug reactions with eosinophilia and systemic symptoms (PT)

305 (0.8)

9 (5)

Events of hepatic disorders reported with terms of Immune system disorder (SOC)

n.d.*

n.d.*

 Hepatitis (PT)

74 (0.2)

3 (2)

 Jaundice (PT)

26 (0.1)

–

 Acute hepatic failure (PT)

12 (< 0.1)

2 (1)

 Hepatic function abnormal (PT)

25 (0.1)

–

 Hepatic enzymes increase (incl. ALT, transaminases) (PT)

52 (0.1)

3 (2)

 Other hepatic terms reported

Not done

4 (2)

Lower respiratory tract inflammatory and immunological conditions (HLGT)

35 (0.1)

2 (1)

Pneumonitis (PT)

9 (< 0.1)

–

Hemolytic anemia, hemolysis, autoimmune hemolytic anemia (PT)**

187 (0.5)

2 (1)

Tubulointerstitial nephritis, nephritis, allergic nephritis (PT)***

160 (0.4)

6 (3)